Jump to content

Setoperone

From Wikipedia, the free encyclopedia
Setoperone
Clinical data
Other namesR-52245; R52245
Drug classSerotonin 5-HT2A receptor antagonist
ATC code
  • None
Identifiers
  • 6-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-7-methyl-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H24FN3O2S
Molar mass401.50 g·mol−1
3D model (JSmol)
  • CC1=C(C(=O)N2CCSC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F
  • InChI=1S/C21H24FN3O2S/c1-14-18(20(27)25-12-13-28-21(25)23-14)8-11-24-9-6-16(7-10-24)19(26)15-2-4-17(22)5-3-15/h2-5,16H,6-13H2,1H3 ☒N
  • Key:RBGAHDDQSRBDOG-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Setoperone (INNTooltip International Nonproprietary Name; USANTooltip United States Adopted Name; developmental code name R-52245) is a compound that is a ligand to the 5-HT2A receptor.[1] It can be radiolabeled with the radioisotope fluorine-18 and used as a radioligand with positron emission tomography (PET). Several research studies have used the radiolabeled setoperone in neuroimaging for the studying neuropsychiatric disorders, such as depression[2] or schizophrenia.[3] The drug was first described by at least 1984.[1]

Chemistry

[edit]

Synthesis

[edit]
Synthesis:[4] Patent (Intermediate 11 & Ex 1):[5] Radiolabelled:[6]

The starting material is called 6-(2-hydroxyethyl)-7-methyl-2,3-dihydro-[1,3]thiazolo[3,2-a]pyrimidin-5-one, CID:15586462 (1). Halogenation of this with hydrobromic acid in acetic acid gives CID:15586463 (2). Sn2 alkylation with 4-(4-fluorobenzoyl)piperidine [56346-57-7] (3) under Finkelstein reaction conditions affords setoperone (4).

See also

[edit]

References

[edit]
  1. ^ a b Elks, J. (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3. Retrieved 17 January 2026.
  2. ^ Jeffrey H. Meyer, Shitij Kapur, Sylvain Houle, Jean DaSilva, Beata Owczarek, Gregory M. Brown, Alan A. Wilson and Sidney H. Kennedy (July 1, 1999). "Prefrontal Cortex 5-HT2 Receptors in Depression: An [18F]Setoperone PET Imaging Study". American Journal of Psychiatry. 156 (7): 1029–1034. doi:10.1176/ajp.156.7.1029. PMID 10401447. S2CID 453720.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Ralph Lewis, Shitij Kapur, Corey Jones, Jean DaSilva, Gregory M. Brown, Alan A. Wilson, Sylvain Houle and Robert B. Zipursky (January 1, 1999). "Serotonin 5-HT2 Receptors in Schizophrenia: A PET Study Using [18F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects". American Journal of Psychiatry. 156 (1): 72–78. doi:10.1176/ajp.156.1.72. PMID 9892300.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Drugs of the Future, 10, 1, 40 (1985).
  5. ^ EP0070053 idem Ludo E. J. Kennis, Josephus C. Mertens, U.S. patent 4,443,451 (1984 to Janssen Pharmaceutica N.V.).
  6. ^ Maziere, B.; Crouzel, C.; Venet, M.; Stulzaft, O.; Sanz, G.; Ottaviani, M.; Sejourne, C.; Pascal, O.; Bisserbe, J.C. (1988). "Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors". International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 15 (4): 463–468. doi:10.1016/0883-2897(88)90018-9.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Setoperone&oldid=1333459038"